Nicholas Keat1, Julia Kenny2, Keguan Chen3, Mayca Onega1, Nadia Garman4, Robert J Slack5, Christine A Parker6, R Thomas Lumbers5, Will Hallett1, Azeem Saleem1, Jan Passchier1, Pauline T Lukey7. 1. Imanova Ltd., London, United Kingdom. 2. In Vitro In Vivo Translation, GlaxoSmithKline R&D, Ware, United Kingdom. 3. Immunogenicity and Clinical Immunology, GlaxoSmithKline R&D, Upper Merion, Pennsylvania. 4. Clinical Operations, GlaxoSmithKline R&D, Stevenage, United Kingdom. 5. Fibrosis Discovery Performance Unit, GlaxoSmithKline R&D, Stevenage, United Kingdom; and. 6. Clinical Imaging, GlaxoSmithKline R&D, Stevenage, United Kingdom. 7. Fibrosis Discovery Performance Unit, GlaxoSmithKline R&D, Stevenage, United Kingdom; and pauline.t.lukey@gsk.com.
Abstract
The αvβ6 integrin is involved in the pathogenesis of cancer and fibrosis. A radiolabeled 20-amino-acid αvβ6-binding peptide, derived from the foot and mouth virus (NAVPNLRGDLQVLAQKVART [A20FMDV2]), has been developed to image αvβ6 levels preclinically. This study was designed to translate these findings into a clinical PET imaging protocol to measure the expression of αvβ6 in humans. Methods: Preclinical toxicology was undertaken, and a direct immunoassay was developed for 4-fluorobenzamide (FB)-A20FMDV2. Four healthy human subjects (2 male and 2 female) received a single microdose of 18F-FB-A20FMDV2 followed by a multibed PET scan of the whole body over more than 3 h. Results: There were no findings in the preclinical toxicology assessments, and no anti-A20FMDV2 antibodies were detected before or after dosing with the PET ligand. The mean and SD of the administered mass of 18F-FB-A20FMDV2 was 8.7 ± 4.4 μg (range, 2.7-13.0 μg). The mean administered activity was 124 ± 20 MBq (range, 98-145 MBq). There were no adverse or clinically detectable pharmacologic effects in any of the subjects. No significant changes in vital signs, laboratory study results, or electrocardiography results were observed. Uptake of radioactivity was observed in the thyroid, salivary glands, liver, stomach wall, spleen, kidneys, ureters, and bladder. Time-activity curves indicated that the highest activity was in the bladder content, followed by the kidneys, small intestine, stomach, liver, spleen, thyroid, and gallbladder. The largest component of the residence times was the voided urine, followed by muscle, bladder, and liver. Using the mean residence time over all subjects as input to OLINDA/EXM, the effective dose was determined to be 0.0217 mSv/MBq; using residence times from single subjects gave an SD of 0.0020 mSv/MBq from the mean. The critical organ was the urinary bladder, with an absorbed dose of 0.18 mGy/MBq. Conclusion: 18F-FB-A20FMDV2 successfully passed toxicology criteria, showed no adverse effects in this first-in-humans study, and has an effective dose that enables multiple scans in a single subject.
The αvβ6 integrin is involved in the pathogenesis of cancer and fibrosis. A radiolabeled 20-amino-acid αvβ6-binding peptide, derived from the foot and mouth virus (NAVPNLRGDLQVLAQKVART [A20FMDV2]), has been developed to image αvβ6 levels preclinically. This study was designed to translate these findings into a clinical PET imaging protocol to measure the expression of αvβ6 in humans. Methods: Preclinical toxicology was undertaken, and a direct immunoassay was developed for 4-fluorobenzamide (FB)-A20FMDV2. Four healthy human subjects (2 male and 2 female) received a single microdose of 18F-FB-A20FMDV2 followed by a multibed PET scan of the whole body over more than 3 h. Results: There were no findings in the preclinical toxicology assessments, and no anti-A20FMDV2 antibodies were detected before or after dosing with the PET ligand. The mean and SD of the administered mass of 18F-FB-A20FMDV2 was 8.7 ± 4.4 μg (range, 2.7-13.0 μg). The mean administered activity was 124 ± 20 MBq (range, 98-145 MBq). There were no adverse or clinically detectable pharmacologic effects in any of the subjects. No significant changes in vital signs, laboratory study results, or electrocardiography results were observed. Uptake of radioactivity was observed in the thyroid, salivary glands, liver, stomach wall, spleen, kidneys, ureters, and bladder. Time-activity curves indicated that the highest activity was in the bladder content, followed by the kidneys, small intestine, stomach, liver, spleen, thyroid, and gallbladder. The largest component of the residence times was the voided urine, followed by muscle, bladder, and liver. Using the mean residence time over all subjects as input to OLINDA/EXM, the effective dose was determined to be 0.0217 mSv/MBq; using residence times from single subjects gave an SD of 0.0020 mSv/MBq from the mean. The critical organ was the urinary bladder, with an absorbed dose of 0.18 mGy/MBq. Conclusion: 18F-FB-A20FMDV2 successfully passed toxicology criteria, showed no adverse effects in this first-in-humans study, and has an effective dose that enables multiple scans in a single subject.
Authors: Sven H Hausner; Richard J Bold; Lina Y Cheuy; Helen K Chew; Megan E Daly; Ryan A Davis; Cameron C Foster; Edward J Kim; Julie L Sutcliffe Journal: Clin Cancer Res Date: 2018-11-06 Impact factor: 12.531
Authors: Pauline T Lukey; Christopher Coello; Roger Gunn; Christine Parker; Frederick J Wilson; Azeem Saleem; Nadia Garman; Maria Costa; Stuart Kendrick; Mayca Onega; Arthur R Kang'ombe; Allan Listanco; James Davies; Joaquim Ramada-Magalhaes; Sara Moz; William A Fahy; Toby M Maher; Gisli Jenkins; Jan Passchier; Richard P Marshall Journal: Eur J Nucl Med Mol Imaging Date: 2019-12-09 Impact factor: 9.236
Authors: Mayca Onega; Christine A Parker; Christopher Coello; Gaia Rizzo; Nicholas Keat; Joaquim Ramada-Magalhaes; Sara Moz; Sac-Pham Tang; Christophe Plisson; Lisa Wells; Sharon Ashworth; Robert J Slack; Giovanni Vitulli; Frederick J Wilson; Roger Gunn; Pauline T Lukey; Jan Passchier Journal: Eur J Nucl Med Mol Imaging Date: 2020-01-03 Impact factor: 9.236